NUP160 and chronic myelogenous leukemia, BCR-ABL1 positive: NUP160 was found to be highly expressed in the peripheral blood or cell lines of patients with chronic myeloid leukemia (CML), inhibiting the sensitivity of CML to imatinib (Zhang et al. 2019).